Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

C A Sabin; A d'Arminio Monforte; N Friis-Moller; R Weber; W M El-Sadr; P Reiss; O Kirk; P Mercie; M G Law; S De Wit; C Pradier; A N Phillips; J D Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs Study Group

doi:10.1086/528862

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

C A Sabin, A d'Arminio Monforte, N Friis-Moller, R Weber, W M El-Sadr, P Reiss, O Kirk, P Mercie, M G Law, S De Wit, C Pradier, A N Phillips, J D Lundgren, Data Collection on Adverse Events of Anti-HIV Drugs Study Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

55 Citationer (Scopus)

Abstract

Udgivelsesdato: 2008-Apr-1

Originalsprog	Engelsk
Tidsskrift	Clinical Infectious Diseases
Vol/bind	46
Udgave nummer	7
Sider (fra-til)	1101-10
Antal sider	9
ISSN	1058-4838
DOI	https://doi.org/10.1086/528862
Status	Udgivet - 2008

Bibliografisk note

Keywords: Adult; Anti-HIV Agents; Antilipemic Agents; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Myocardial Infarction

Adgang til dokumentet

10.1086/528862

Citationsformater

Sabin, C. A., d'Arminio Monforte, A., Friis-Moller, N., Weber, R., El-Sadr, W. M., Reiss, P., Kirk, O., Mercie, P., Law, M. G., De Wit, S., Pradier, C., Phillips, A. N., Lundgren, J. D., & Data Collection on Adverse Events of Anti-HIV Drugs Study Group (2008). Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clinical Infectious Diseases, 46(7), 1101-10. https://doi.org/10.1086/528862

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. / Sabin, C A; d'Arminio Monforte, A; Friis-Moller, N; Weber, R; El-Sadr, W M; Reiss, P; Kirk, O; Mercie, P; Law, M G; De Wit, S; Pradier, C; Phillips, A N; Lundgren, J D; Data Collection on Adverse Events of Anti-HIV Drugs Study Group.

I: Clinical Infectious Diseases, Bind 46, Nr. 7, 2008, s. 1101-10.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Sabin, CA, d'Arminio Monforte, A, Friis-Moller, N, Weber, R, El-Sadr, WM, Reiss, P, Kirk, O, Mercie, P, Law, MG, De Wit, S, Pradier, C, Phillips, AN, Lundgren, JD & Data Collection on Adverse Events of Anti-HIV Drugs Study Group 2008, 'Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction', Clinical Infectious Diseases, bind 46, nr. 7, s. 1101-10. https://doi.org/10.1086/528862

Sabin, C A ; d'Arminio Monforte, A ; Friis-Moller, N ; Weber, R ; El-Sadr, W M ; Reiss, P ; Kirk, O ; Mercie, P ; Law, M G ; De Wit, S ; Pradier, C ; Phillips, A N ; Lundgren, J D ; Data Collection on Adverse Events of Anti-HIV Drugs Study Group. / Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. I: Clinical Infectious Diseases. 2008 ; Bind 46, Nr. 7. s. 1101-10.

@article{1ea0f7a0ff3811ddb219000ea68e967b,

title = "Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction",

abstract = "BACKGROUND: Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. METHODS: The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. RESULTS: The proportion of patients at high risk of CVD increased from 35.3% during 1999-2000 to 41.3% during 2005-2006. Of 28,985 patients, 2801 (9.7%) initiated lipid-lowering therapy; initiation of lipid-lowering therapy was more common for those with abnormal lipid values and those with traditional risk factors for CVD (male sex, older age, higher body mass index [calculated as the weight in kilograms divided by the square of the height in meters], family and personal history of CVD, and diabetes mellitus). After controlling for these, use of lipid-lowering drugs became relatively less common over time. The incidence of myocardial infarction (0.32 cases per 100 person-years [PY]; 95% confidence interval [CI], 0.29-0.35 cases per 100 PY) appeared to remain stable. However, after controlling for changes in risk factors for CVD, the rate decreased over time (relative rate in 2003 [compared with 1999-2000], 0.73 cases per 100 PY [95% CI, 0.50-1.05 cases per 100 PY]; in 2004, 0.64 cases per 100 PY [95% CI, 0.44-0.94 cases per 100 PY]; in 2005-2006, 0.36 cases per 100 PY [95% CI, 0.24-0.56 cases per 100 PY]). Further adjustment for lipid levels attenuated the relative rates towards unity (relative rate in 2003 [compared with 1999-2000], 1.06 cases per 100 PY [95% CI, 0.63-1.77 cases per 100 PY]; in 2004, 1.02 cases per 100 PY [95% CI, 0.61-1.71 cases per 100 PY]; in 2005-2006, 0.63 cases per 100 PY [95% CI, 0.36-1.09 cases per 100 PY]). CONCLUSIONS: Although the CVD risk profile among patients in the Data Collection on Adverse Events of Anti-HIV Drugs Study has decreased since 1999, rates have remained relatively stable, possibly as a result of a more aggressive approach towards managing the risk of CVD.",

author = "Sabin, {C A} and {d'Arminio Monforte}, A and N Friis-Moller and R Weber and El-Sadr, {W M} and P Reiss and O Kirk and P Mercie and Law, {M G} and {De Wit}, S and C Pradier and Phillips, {A N} and Lundgren, {J D} and {Data Collection on Adverse Events of Anti-HIV Drugs Study Group}",

note = "Keywords: Adult; Anti-HIV Agents; Antilipemic Agents; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Myocardial Infarction",

year = "2008",

doi = "10.1086/528862",

language = "English",

volume = "46",

pages = "1101--10",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

AU - Sabin, C A

AU - d'Arminio Monforte, A

AU - Friis-Moller, N

AU - Weber, R

AU - El-Sadr, W M

AU - Reiss, P

AU - Kirk, O

AU - Mercie, P

AU - Law, M G

AU - De Wit, S

AU - Pradier, C

AU - Phillips, A N

AU - Lundgren, J D

AU - Data Collection on Adverse Events of Anti-HIV Drugs Study Group

N1 - Keywords: Adult; Anti-HIV Agents; Antilipemic Agents; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Myocardial Infarction

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. METHODS: The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. RESULTS: The proportion of patients at high risk of CVD increased from 35.3% during 1999-2000 to 41.3% during 2005-2006. Of 28,985 patients, 2801 (9.7%) initiated lipid-lowering therapy; initiation of lipid-lowering therapy was more common for those with abnormal lipid values and those with traditional risk factors for CVD (male sex, older age, higher body mass index [calculated as the weight in kilograms divided by the square of the height in meters], family and personal history of CVD, and diabetes mellitus). After controlling for these, use of lipid-lowering drugs became relatively less common over time. The incidence of myocardial infarction (0.32 cases per 100 person-years [PY]; 95% confidence interval [CI], 0.29-0.35 cases per 100 PY) appeared to remain stable. However, after controlling for changes in risk factors for CVD, the rate decreased over time (relative rate in 2003 [compared with 1999-2000], 0.73 cases per 100 PY [95% CI, 0.50-1.05 cases per 100 PY]; in 2004, 0.64 cases per 100 PY [95% CI, 0.44-0.94 cases per 100 PY]; in 2005-2006, 0.36 cases per 100 PY [95% CI, 0.24-0.56 cases per 100 PY]). Further adjustment for lipid levels attenuated the relative rates towards unity (relative rate in 2003 [compared with 1999-2000], 1.06 cases per 100 PY [95% CI, 0.63-1.77 cases per 100 PY]; in 2004, 1.02 cases per 100 PY [95% CI, 0.61-1.71 cases per 100 PY]; in 2005-2006, 0.63 cases per 100 PY [95% CI, 0.36-1.09 cases per 100 PY]). CONCLUSIONS: Although the CVD risk profile among patients in the Data Collection on Adverse Events of Anti-HIV Drugs Study has decreased since 1999, rates have remained relatively stable, possibly as a result of a more aggressive approach towards managing the risk of CVD.

AB - BACKGROUND: Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. METHODS: The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. RESULTS: The proportion of patients at high risk of CVD increased from 35.3% during 1999-2000 to 41.3% during 2005-2006. Of 28,985 patients, 2801 (9.7%) initiated lipid-lowering therapy; initiation of lipid-lowering therapy was more common for those with abnormal lipid values and those with traditional risk factors for CVD (male sex, older age, higher body mass index [calculated as the weight in kilograms divided by the square of the height in meters], family and personal history of CVD, and diabetes mellitus). After controlling for these, use of lipid-lowering drugs became relatively less common over time. The incidence of myocardial infarction (0.32 cases per 100 person-years [PY]; 95% confidence interval [CI], 0.29-0.35 cases per 100 PY) appeared to remain stable. However, after controlling for changes in risk factors for CVD, the rate decreased over time (relative rate in 2003 [compared with 1999-2000], 0.73 cases per 100 PY [95% CI, 0.50-1.05 cases per 100 PY]; in 2004, 0.64 cases per 100 PY [95% CI, 0.44-0.94 cases per 100 PY]; in 2005-2006, 0.36 cases per 100 PY [95% CI, 0.24-0.56 cases per 100 PY]). Further adjustment for lipid levels attenuated the relative rates towards unity (relative rate in 2003 [compared with 1999-2000], 1.06 cases per 100 PY [95% CI, 0.63-1.77 cases per 100 PY]; in 2004, 1.02 cases per 100 PY [95% CI, 0.61-1.71 cases per 100 PY]; in 2005-2006, 0.63 cases per 100 PY [95% CI, 0.36-1.09 cases per 100 PY]). CONCLUSIONS: Although the CVD risk profile among patients in the Data Collection on Adverse Events of Anti-HIV Drugs Study has decreased since 1999, rates have remained relatively stable, possibly as a result of a more aggressive approach towards managing the risk of CVD.

U2 - 10.1086/528862

DO - 10.1086/528862

M3 - Journal article

C2 - 18461712

VL - 46

SP - 1101

EP - 1110

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -